These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38897673)

  • 1. Antiplatelet Therapy, Pretreatment, and Primary PCI: Every Minute Counts.
    Silvain J; Montalescot G; Guedeney P
    J Am Coll Cardiol; 2024 Jun; 83(25):2640-2642. PubMed ID: 38897673
    [No Abstract]   [Full Text] [Related]  

  • 2. Timing of P2Y
    Almendro-Delia M; Hernández-Meneses B; Padilla-Rodríguez G; Blanco-Ponce E; Arboleda-Sánchez JA; Rodríguez-Yáñez JC; Soto-Blanco JM; Fernández-García I; Castillo-Caballero JM; García-Rubira JC; Hidalgo-Urbano R
    J Am Coll Cardiol; 2024 Jun; 83(25):2629-2639. PubMed ID: 38897672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI.
    Alexopoulos D; Gkizas V; Patsilinakos S; Xanthopoulou I; Angelidis C; Anthopoulos P; Makris G; Perperis A; Karanikas S; Koutsogiannis N; Davlouros P; Deftereos S; Chiladakis J; Hahalis G
    J Am Coll Cardiol; 2013 Sep; 62(10):940-1. PubMed ID: 23747780
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiplatelet therapy in STEMI undergoing primary PCI: when, which one and how long.
    Baralis G; Rossini R; Musumeci G
    Minerva Cardioangiol; 2018 Aug; 66(4):422-428. PubMed ID: 29458246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments in antiplatelet therapy after percutaneus coronary intervention.
    Yildiz M; Yildiz BS; Gursoy MO; Akin I
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(3):225-30. PubMed ID: 25174713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized ADP-receptor inhibition strategy and outcomes following primary PCI for STEMI (PASTOR study).
    Mikkelsson J; Paana T; Lepantalo A; Karjalainen PP
    Int J Cardiol; 2016 Jan; 202():463-6. PubMed ID: 26436674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment with Antiplatelet Agents in the Setting of Percutaneous Coronary Intervention: When and Which Drugs?
    Capodanno D; Angiolillo DJ
    Interv Cardiol Clin; 2017 Jan; 6(1):13-24. PubMed ID: 27886816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry.
    Godschalk TC; Byrne RA; Adriaenssens T; Malik N; Feldman LJ; Guagliumi G; Alfonso F; Neumann FJ; Trenk D; Joner M; Schulz C; Steg PG; Goodall AH; Wojdyla R; Dudek D; Wykrzykowska JJ; Hlinomaz O; Zaman AG; Curzen N; Dens J; Sinnaeve P; Desmet W; Gershlick AH; Kastrati A; Massberg S; Ten Berg JM;
    JACC Cardiovasc Interv; 2017 Dec; 10(24):2548-2556. PubMed ID: 29268884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.
    Gajos G; Rostoff P; Undas A; Piwowarska W
    J Am Coll Cardiol; 2010 Apr; 55(16):1671-8. PubMed ID: 20394870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current management and quality of life of patients with acute coronary syndrome undergoing percutaneous coronary intervention in Greece: 12-Month results from antiplatelet therapy observational study II (APTOR II).
    Pavlides G; Drossinos V; Dafni C; Altsitzoglou P; Antoniadis A; Manolis AS; Tsioufis C; Goudevenos I; Kochiadakis G; Alexopoulos D
    Hellenic J Cardiol; 2013; 54(4):255-63. PubMed ID: 23912917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention.
    Li Y; Tai BC; Sia W; Phua QH; Richards MA; Low A; Chan KH; Teo SG; Sim TB; Lee CH; Roe MT; Yeo TC; Tan HC; Chan MY
    J Thromb Thrombolysis; 2012 Nov; 34(4):499-505. PubMed ID: 22855283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet and anticoagulation regimen in patients with mechanical valve undergoing PCI - State-of-the-art review.
    Gajanana D; Rogers T; Iantorno M; Buchanan KD; Ben-Dor I; Pichard AD; Satler LF; Torguson R; Okubagzi PG; Waksman R
    Int J Cardiol; 2018 Aug; 264():39-44. PubMed ID: 29685692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery.
    Ferreiro JL; Homs S; Berdejo J; Roura G; Gómez-Lara J; Romaguera R; Teruel L; Sánchez-Elvira G; Marcano AL; Gómez-Hospital JA; Angiolillo DJ; Cequier Á
    Thromb Haemost; 2013 Jul; 110(1):110-7. PubMed ID: 23615769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).
    Udell JA; Braunwald E; Antman EM; Murphy SA; Montalescot G; Wiviott SD
    JACC Cardiovasc Interv; 2014 Jun; 7(6):604-12. PubMed ID: 24947719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Temporal evolution of antithrombotic therapy use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in Italy: comparison between the EYESHOT and SCOPE registries].
    De Luca L; Pennacchi M; Musumeci G; D'Ascenzo F; Gallo P; Rigattieri S; Granatelli A; Berti S; Gulizia MM; De Servi S; Bolognese L;
    G Ital Cardiol (Rome); 2018 Feb; 19(2):101-110. PubMed ID: 29531382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet Therapy in Percutaneous Coronary Intervention.
    Fanaroff AC; Rao SV
    Interv Cardiol Clin; 2016 Apr; 5(2):221-237. PubMed ID: 28582206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial.
    Zheng YY; Wu TT; Yang Y; Hou XG; Gao Y; Chen Y; Yang YN; Li XM; Ma X; Ma YT; Xie X
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):211-221. PubMed ID: 31603191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single antiplatelet therapy after percutaneous coronary intervention in patients allergic to aspirin.
    Agarwal SK
    Cardiovasc Revasc Med; 2014; 15(5):308-10. PubMed ID: 24880912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Upstream administration of oral antiplatelet agents in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention].
    Ferlini M; Mafrici A; Marzegalli M; Piccaluga E; Sponzilli C; Bramucci E; Visconti LO
    G Ital Cardiol (Rome); 2014 Feb; 15(2):90-8. PubMed ID: 24625848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment with dual antiplatelet therapy in patients with ST-elevation myocardial infarction.
    Yudi MB; Farouque O; Andrianopoulos N; Ajani AE; Brennan A; Lefkovits J; Reid CM; Chan W; Duffy SJ; Clark DJ;
    Catheter Cardiovasc Interv; 2018 Aug; 92(2):E98-E105. PubMed ID: 28963757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.